IP Library Granted Patent US 11,919,888
Granted Patent B2
US 11,919,888 · App. 18/173,573 · Granted Mar 5, 2024

Neprilysin inhibitors

Inventors: Melissa Fleury (Brisbane, CA); Adam D. Hughes (Half Moon Bay, CA)
Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
C07D405/12A61K31/415A61K31/4192A61K31/42A61K31/421A61K45/06C07D231/14C07D231/20C07D249/04C07D261/18C07D263/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,919,888
App. No.
18/173,573
Granted
Mar 5, 2024
Kind
B2
Abstract

In one aspect, the invention relates to compounds having the formula: where X, R a , R b , R 2 , and R 7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Claims (11)

1. A method of making Compound 6N:

or a pharmaceutically acceptable salt thereof, comprising:

contacting Compound 2:

with palladium on carbon and hydrogen gas under conditions sufficient to provide Compound 6N or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , further comprising contacting Compound 1:

with 3-hydroxyisoxazole-5-carboxylic acid under conditions sufficient to provide Compound 2.

3. The method of claim 2 , further comprising contacting a compound having the structure:

with hydrochloric acid under conditions sufficient to provide Compound 1.

4. The method of claim 1 , wherein the conditions comprise ethyl acetate and acetic acid.

5. The method of claim 2 , wherein the conditions further comprise N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate and N-ethyl-N-isopropylpropan-2-amine.

6. The method of claim 3 , wherein the conditions comprise acetonitrile and dioxane.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2026
From: THERAVANCE BIOPHARMA R&D IP, LLC
To: EONHF, INC.
Reel/Frame 075494/0756 →
Continuity (10)
Continuation 17445096 · Aug 16, 2021
Continuation 16739525 · Jan 10, 2020
Continuation 16209112 · Dec 4, 2018
Continuation 15841749 · Dec 14, 2017
Continuation 15497508 · Apr 26, 2017
Continuation 14812095 · Jul 29, 2015
Continuation 13961269 · Aug 7, 2013
Provisional Application 61774163 · Mar 7, 2013
Provisional Application 61680804 · Aug 8, 2012
Related Publication 20230312537A1 · Oct 5, 2023